Research Meetings
August through September 2016

September 14, 2016 ( Wednesday )

4:00pm - 5:00pm
Aab CVRI Seminar Series

SPEAKER: Nigel Mackman, B.Sc., Ph.D., FAHA Director of the UNC McAllister Heart Institute School of Medicine, UNC-Chapel Hill, Immunology University of North Carolina at Chapel Hill Chapel Hill, NC

TITLE OF TALK: "Roles of Tissue Factor in Hemostasis, Thrombosis, Cardiac Injury and Viral Infection"

ABSTRACT: Dr. Mackman is interested in mechanisms of hemostasis and thrombosis, and the crosstalk between coagulation and inflammation. In particular, I study the role of tissue factor (TF), coagulation proteases, protease activated receptors (PARs) and microvesicles (MVs) in ischemia-reperfusion (I/R) injury, cancer, sickle cell disease, obesity, viral infection, atherosclerosis and liver injury. My lab has generated several unique mouse lines that have altered levels of TF, PAR1 and PAR2. For instance, we have made mice expressing only ~1% of wild-type TF levels. These mice have been used extensively by us and others to study the role of TF in hemostasis, thrombosis and other processes, such as inflammation in sickle cell disease. My lab also generated TF floxed mice that allows deletion of the TF gene in different cell types by crossing these mice with mice expressing the Cre recombinase in a cell type-specific manner.

Location:  CVRI Conf. Room # G.11211/G.11213

Posted by:  Jacqueline Velazquez, Cardiovascular Research Institute, 18-Jul-16 10:20am ET

September 19, 2016 ( Monday )

12:00pm - 1:00pm
Microbiology and Immunology Department Seminar

Leonidas Stamatatos Ph.D. Member, Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division Immunology and Vaccine Development Program

"Novel immunogens to initiate the development of HIV-1 broadly neutralizing antibodies during vaccination"

Host: Stephen Dewhurst, PhD

Monday, September 19, 2016 12:00-1:00 PM Upper Auditorium (Room 3-7619)

Seminar Abstract: In the past 5-6 years, it became apparent that germline (GL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs), do not display measurable binding to the HIV-1 envelope glycoprotein (Env). These observations created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs during vaccination and led to the 'germline-targeting' immunization approach. New Env-based immunogens had to be designed in order to activate naïve B cells expressing the germline B cell receptors of bNAbs in vivo. These immunogen-design efforts and the most recent immunizations studies with 'germline-targeting' immunogens will be discussed.

Location:  Upper Auditorium (3-7619)

Posted by:  Brenda Knorr, Micro & Immunolgy, 17-Aug-16 11:58am ET